Seattle-based CTI BioPharma Corp. is a biopharmaceutical company that is making waves in the United States through its latest acquisition, development, and commercialization of novel targeted therapies for blood-related cancers. The company has developed VONJO (pacritinib), a potent oral kinase inhibitor that targets JAK2, FLT3, IRAK1, and CSF1R. VONJO is effective in the treatment of adult patients with myelofibrosis. CTI BioPharma has secured license and collaboration agreements with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd to bolster its market position. Founded in 1991 as Cell Therapeutics, the company changed its name to CTI BioPharma Corp. in May 2014 to reflect its new direction.